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ABSTRACT
This article, co-authored by a patient affected by
bilateral, recurrent, atypical optic neuritis, and
clinicians, discusses the mental burden of living
with uncertainty and the possibility of further
sight loss, along with the side effects of treat-
ment. The patient shares some of the chal-
lenges, coping strategies, and the value they
found in creating and participating in a patient
support group. The physicians consider whether
current clinical measures adequately capture
the outcomes that matter to patients and dis-
cuss the role for patient-reported outcome
measures (PROMs). We identify technological
advances that are lowering traditional barriers
to the use of PROMs in research and routine
clinical care and look towards new PROM
instruments enhancing shared patient-physi-
cian care in the future.
PLAIN LANGUAGE SUMMARY
In this patient-physician perspective article, we
share the story of a patient affected by an
autoimmune disease that attacks the nerves
connecting the eyes and the brain and reflect
back physicians’ perspectives on the disease and
the patient’s experience of it. In a compelling
account, we gain some understanding of what it
might be like to live with the fear of unpre-
dictable episodes of sudden, recurrent sight loss
and the important impacts that this has on a
patient’s life and mental wellbeing. We recog-
nize that the outcome metrics that physicians
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usually focus on, such as measurement of vision
and imaging of the optic nerve, do not fully
capture the outcomes that most matter to the
patient. We explore patient-reported outcome
measures that go some way towards bridging
this gap. Finally, we consider the technological
advances that will make more comprehensive
capture of the patient experience a reality in
future clinical practice and research, supporting
both patients and physicians to optimize shared
care.
Keywords: Chronic relapsing inflammatory
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Key Summary Points
Patient perspectives on the impact of optic
neuritis have been seldom reported in the
medical literature.
There is growing recognition of the
importance of the ‘patient voice’ in
ophthalmology research and clinical
practice.
Patient accounts provide valuable insights
into the outcomes and metrics that matter
most to patients.
A few patient-reported outcome measures
have been developed in neuro-
ophthalmology, and in multiple sclerosis
and neuromyelitis optica spectrum
disorder specifically. In our view, these are
not yet psychometrically optimized for
use in optic neuritis patients in routine
clinical practice or clinical trials.
Technological developments are
overcoming traditional barriers to the
routine use of comprehensive patient-
reported outcome measures.
PATIENT PERSPECTIVE
I was 28 when, 12 years ago, I felt a twinge in
my right eye after a mild flu. Not thinking
anything of it, I gave it little thought until, after
2 weeks, the pain had become constant. After
ineffective antibiotic treatment, I was referred
to the hospital, where they established I had
optic nerve inflammation and only 40% of the
vision in my right eye remained. With intra-
venous prednisone therapy my eyesight
improved up to 80%, but after 2 weeks it drop-
ped again, this time to no perception of light in
just 36 h. Subsequent intravenous prednisone
did not help. An MRI (magnetic resonance
imaging scan) ruled out multiple sclerosis and I
was told this was an episode of bad luck: My
immune system had probably confused my eye
nerve with a virus and attacked it. Living with
only one seeing eye is actually not a big change
(unless you have an aspiring squash career,
which I did not), and I got used to it in a matter
of weeks. But 7 years after this episode, I felt the
same tingling sensation in my left eye. Losing
one eye is fine, but going blind in both is a
completely different matter. I was diagnosed
with a chronic relapsing inflammatory optic
neuropathy (CRION). Intravenous prednisone
when attacks flare up and daily prednisone
tablets have since helped to retain the eyesight
in my left eye. In spite of this treatment, I get
two or three attacks per year, and although
repeat OCT (optical coherence tomography)
scans show that the nerve damage hasn’t dete-
riorated much, so far I’ve been lucky.
The above is roughly what I tell people when
they ask me about it. The current medical world
is mostly focused on traditional measurable
metrics. For me, the key metrics my doctors use
include visual acuity, OCT scans, and intraoc-
ular pressure. But there are other unquantifiable
factors, such as mental aspects, convenience of
treatment, and quality of life, that in the cur-
rent medical climate get less attention. In my
experience this can leave important patient
questions unaddressed, in turn missing an
opportunity to do better in helping patients
deal with their disease and its treatment.
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Take mental stress for instance. In my case,
losing sight in one eye was not a big deal. But
losing sight in my other eye would drastically
change my life. I have a 16-month-old son at
home, and I want to see him growing up. So
naturally, I want to do all I can to keep my
eyesight, and my independence. I’m convinced
human beings in general aren’t good at dealing
with the unknown. We have a natural tendency
to look for (a sense of) control. We want to
eliminate the distress of the unknown, so we’re
always looking for cognitive closure. And when
the medical world cannot help you in achieving
this sense of control, you start to venture out by
yourself to see what you can do. The overarch-
ing question for me is, ‘‘what is causing this,
and what can I do to limit the attacks and keep
my eyesight?’’ Given the rising incidence of
autoimmune diseases in the population, it
seems to point at environmental factors (vs.
genetic factors), so I wonder what I can do to
change my environment, to balance my
immune system again. I’ve looked in various
directions: Are autoimmune disorders related to
stress? If so, how can I minimize stress? What
role does diet play? What is the relationship
between gut health and the immune system?
Can more physical activity and more sleep have
a positive effect?
To find answers to these questions I started
to read up online. But as most doctors have
probably experienced with patients, Google will
find any correlation you want. Confirmation
bias thrives online. And it’s very easy to get
down a rabbit hole or into an echo chamber on
topics that might lack a scientific evidence base.
I started changing my routines. What I eat,
when I eat, when and how much I work out,
and my sleeping patterns. With each change I
felt hopeful about finding the holy grail, but
then the next attack would come, prompting
me to re-evaluate and correct course.
For most patients I’m convinced the mental
burden is the most difficult part of their disease.
Regardless if it’s autoimmune disease, cancer, or
even a complicated fracture. Variations on
‘‘What will happen to me in the future?’’ For me
the constant question is, ‘‘Will I go blind’’, and
the underlying question is, ‘‘How is my eyesight
right now? Am I seeing less or more?’’ When I
have an attack, I’m re-evaluating my eyesight
up to 1000 times a day: ‘‘Should I be able to read
that sign across the road? Is it the lighting in the
room or is it my vision?’’ And so on. This ‘‘Am I
going blind’’ Sword of Damocles completely
occupies me. I’m afraid my body will not
respond quickly enough to treatment of an
attack, which will further damage my optic
nerve. But at the same time, I do not want to
increase the dose of my medication unneces-
sarily, as this could cause more side effects.
When I go to clinic for a check-up, the visual
acuity and OCT results do not always match up
with my experience of the quality of my eye-
sight. All the while, I try not to let it occupy me
too much, as it puts more mental stress on my
body, and it feels like this might further create a
negative spiral. But it’s like the pink elephant in
the room: impossible not to think about it
when someone tells you not to! I’m confronted
with the quality of my eyesight every waking
moment, so it’s more difficult to shut down that
thought process. These mental struggles are
inherent to all diseases—my situation is far
from unique. And I understand that some doc-
tors might think it’s futile to discuss this aspect
with the patient as there are often no clear
answers or solutions to give. My point is that
patients will venture out themselves if not dis-
cussed. Our natural tendency is to want to fill
the void of not knowing, and putting this
mental aspect more central in the treat-
ment/communication with the patient can help
patients, even if the answers are not there.
I feel lucky to have a great relationship with
my neuro-ophthalmologist, and this has helped
me a lot. Through discussing the mental
aspects, my doctor floated the idea of creating a
patient group to create a space where similar
patients can find information and share expe-
riences. Experiences of what has helped them
personally, and what hasn’t. We share thought
processes around dealing with the disease and
keep each other informed of developments in
treatments. The patient group helps to sift
through the forest of articles, theories, and
possible solutions and helps us to better avoid
the confirmation bias when venturing out to
find answers alone. It has helped us share best
practices. One example, for instance, is how to
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lose water retained by your body due to the
prednisone. I experimented with a cleanse diet
of 1 week where I only ate greens, nuts, and
apples. No caffeine, carbs, alcohol, salt, sugar,
and fats. I lost nearly a kilo a day throughout
the cleanse, and repeat it every so often. It helps
me to lower my internal pressure and avoids me
looking bloated. Though small, these are
important victories in dealing with this disease
and having a patient group is a great way to be
able to share and discuss.
PHYSICIAN PERSPECTIVE
‘‘…and now come and sit beside me for a
little while, and touch me with your hand.
For I cannot see you, Charley; I am blind.’’
These are the words of a young woman to
her child, after discovering that she had lost her
vision. The quote is taken from the novel Bleak
House by Charles Dickens (1812–1870) [1]. In
this novel, the time course and clinical signs of
a disease process, which could have resulted
from simultaneous bilateral optic neuritis or
chiasmitis, are carefully married up chronolog-
ically with the emotions and social interactions
of the main character, Esther Summerville. This
story predates discovery of the ophthalmo-
scope, the clinical definition of optic neuritis,
and any form of treatment. Yet the human
thoughts and emotions are little different
today: ‘‘I have a 16-month-old child’’; ‘‘I want to
see him grow up’’; ‘‘Will I go blind?’’ The last
question is difficult to answer, for whilst we
now have treatment options, they may fail in
some individuals and in differing types of optic
neuritis.
Optic neuritis is an important cause of
potentially irreversible vision impairment [2].
The most typical cause is a demyelinating
inflammatory lesion, which can be isolated or
associated with multiple sclerosis. Patients with
typical optic neuritis usually experience good
recovery of their visual acuity in the first month
after the vision loss, without any treatment,
although the quality of the recovered vision,
and especially the contrast sensitivity or colour
perception, may be worse than before. In
contrast, ‘atypical’ causes of optic neuritis may
present with more severe vision loss (e.g. visual
acuity worse than 6/60 at onset), bilateral
involvement, and/or no pain on eye movement.
These cases usually require urgent high-dose
corticosteroid therapy, and some, including
CRION, are ‘steroid dependent’, meaning that
the disease often relapses when the steroid dose
is weaned or discontinued. Therefore, second-
line steroid-sparing agents (e.g. azathioprine)
are required in these patients, aiming to reduce
the risk of steroid side effects and further vision
loss or neurological morbidity resulting from
relapses [3]. Plasma exchange, intravenous
immunoglobulin, and biological therapies are
also used.
The patient outlines how the impacts of
optic neuritis and its treatment extend far
beyond the limited visual function measures
and OCT imaging parameters monitored in
clinic to encroach upon many different
domains of quality of life. There is growing
recognition of the value of, and need for,
patient-reported outcome measures in medicine
and ophthalmology [4, 5]. Few tools have been
developed to date for neuro-ophthalmology,
and optic neuritis specifically. For example, the
neuro-ophthalmic supplement to the National
Eye Institute Visual Functioning Questionnaire
(NEI-VFQ) includes ten questions [6]. These
include questions on visual symptoms, perfor-
mance in vision-related daily activities, and
appearance. This tool has been used in optic
neuritis clinical trials [7]. However, it covers
only three domains of quality of life, and the
composite summary score lacks psychometric
validity, and is not amenable to parametric
statistical analysis [8, 9]. More recently, a
46-item instrument was developed for neu-
romyelitis optica spectrum disorder, one rare
cause of optic neuritis [10]. This includes ques-
tions on a large number of quality of life
domains, including vision and vision-related
functioning, impacts on life goals and roles,
general health-related functioning, mobility,
bladder function, bowel function, sexual func-
tion, mood, pain, general fatigue, and cogni-
tion. A systematic review of PROM instruments
applicable in optic neuritis is underway and will
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report on the psychometric properties and
quality of available instruments [11].
To overcome some of the psychometric
limitations of PROMs assessing quality of life in
other ophthalmic diseases (e.g. diabetic
retinopathy and hereditary retinal disease),
comprehensive, Rasch-validated multi-dimen-
sional instruments with interval scoring are
being developed [12, 13]. These capture over ten
quality of life domains that matter to patients,
have interval scale properties, and yield para-
metrically distributed continuous outcome
measures. These ‘third-generation’ PROM tools
have the potential to transform clinical trial
outcome measures and routine patient care [5].
Technological advances are rapidly address-
ing the traditional barriers to the integration of
PROMs in clinical medicine. PROMs can now be
administered on phones, tablets, and comput-
ers, with software to overcome low vision, lit-
eracy, and language barriers to completion,
with computer-adaptive testing to reduce time
response burden, and utilizing cloud-based data
storage and integration platforms to link PROM
outcomes into the electronic medical record for
virtual review by physicians [14]. Iterative,
patient-involved development of such PROM
tools has the potential to transform both
patient and physician experience, enhancing
the potential for truly shared care. This article is
based on previously conducted studies and does
not contain any studies with human partici-
pants or animals performed by any of the
authors.
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